Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) is pleased to provide a corporate update and summarized discussion on the results for its first year of operations since the acquisition of Bioganix®.
Read more
Relevium Technologies Announces Conversion of Debentures and Strenghtens Balance Sheet
Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has received notices to convert (the "Conversion") all of the principal amount outstanding of the remaining debentures due June 2019 (the "Debentures) into common shares of the Company (the "Common Shares") at a price of 0.15$ per share.
Read more
Relevium Targets 30 New Bioganix® Gold Products in Walmart by Year End and Prepares to Launch in Canada
Following the successful initial test launch of three (3) SKUs, the Company is now ready to introduce up to thirty (30) new SKUs of its Bioganix® Gold Series formulated products before the end of this year. The Company has also begun the regulatory and compliance process to launch its formulated products in the Canadian market and plans to test walmart.ca as soon as the products obtain natural health product approvals from Health Canada.
Read more
Relevium’s Bioganix® Now Live on Amazon.co.uk
Sept. 20, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce that the Bioganix® brand is now available for purchase in the United Kingdom (“UK”) on the Amazon.co.uk platform.
Read more